Back to Search
Start Over
Treatment of myelodysplastic syndromes with retinoic acid and 1α-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study
- Source :
- European Journal of Haematology. 45:255-261
- Publication Year :
- 2009
- Publisher :
- Wiley, 2009.
-
Abstract
- 63 evaluable patients with myelodysplastic syndromes (MDS) and 15 with acute myelogenous leukemia (AML) were randomized between low-dose ara-C (arm A) and low dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3) (arm B). 69 patients were evaluable and 18 (26.1%) responded to therapy. The addition of 13-CRA and 1 alpha D3 had no positive influence on survival of the patients, remission rates or duration of remissions. 12/27 patients in arm A and 6/29 patients in arm B progressed from MDS to AML during the course of the study (p = 0.0527). Arm B gave significantly more side-effects than arm A (p = 0.005). Therapeutic effects of 13-CRA and 1 alpha D3 on MDS is not supported by this study. However, an inhibiting effect on AML development in some MDS subgroups cannot be excluded.
- Subjects :
- Vitamin
medicine.medical_specialty
Chemotherapy
business.industry
Myelodysplastic syndromes
medicine.medical_treatment
Therapeutic effect
Alpha (ethology)
Hematology
General Medicine
medicine.disease
Gastroenterology
Myelogenous
chemistry.chemical_compound
Leukemia
Endocrinology
chemistry
hemic and lymphatic diseases
Internal medicine
medicine
Cytarabine
business
medicine.drug
Subjects
Details
- ISSN :
- 16000609 and 09024441
- Volume :
- 45
- Database :
- OpenAIRE
- Journal :
- European Journal of Haematology
- Accession number :
- edsair.doi...........69576435c956b265e5ac0bc545f817cc